AL-3778 + entecavir

AL-3778 + entecavir is a combination of two antiviral agents under investigation for the treatment of chronic hepatitis B virus (HBV) infection. **AL-3778** (formerly NVR-3-778) is a first-in-class small molecule core protein inhibitor that interferes with HBV core protein assembly, leading to aberrant capsid formation and inhibition of multiple steps in the HBV lifecycle, including viral replication. **Entecavir** is an orally administered nucleoside analogue that inhibits HBV polymerase, thereby impairing viral DNA synthesis. The combination is designed to act synergistically by targeting distinct steps in the HBV replication process. AL-3778 was initially developed by Novira Therapeutics, which was later acquired by Johnson & Johnson, and subsequent studies have been sponsored by Alios BioPharma. The combination has been studied in phase 1 trials to assess drug-drug interaction, safety, and pharmacokinetics in healthy volunteers and treatment-naïve patients with chronic hepatitis B[1][3][6].

Other names

NVR-3-778 + entecavir